Skip to main content

Table 1 Subject demographic and clinical characteristics (N = 100)

From: A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation

Characteristic

 

Race,%

 

 White

100

Gender,%

 

 Male

48

 Female

52

Age at enrollment

 

 ≤6 mo,%

52

 <12 mo,%

73

 Mean (SD), mo

8.2 (6.3)

 Median (range), mo

6.0 (<1 − 24.0)

Mean (SD) birth weight, kg

2.14 (1.02)

Mean (SD) gestational age, wk

33.4 (5.1)

Medical history,%

 

 Pulmonary*

68

  Respiratory distress syndrome/BPD

52

  Pneumonia

25

  Bronchitis/bronchiolitis

15

  Asthma/reactive airway disease

8

  RSV-related LRTI

1

 Cardiovascular

61

  Murmur

42

    Pathologic

30

    Functional

12

 Congenital heart disease

41

  Acyanotic

28

  Cyanotic

13

 Pulmonary hypertension

10

 Congestive heart failure

7

 Cardiac arrhythmia

1

Hospitalized at birth in intensive/critical care unit,%

67

Hospitalized after birth, prior to study enrollment,%

64

  1. BPD bronchopulmonary dysplasia; LRTI lower respiratory tract infection; RSV respiratory syncytial virus.
  2. *Subjects could contribute to more than 1 category.